Lu-177-Rituximab
177Lu-Rituximab is the Lutetium-177 labeled analogue of 131I-Tositumomab (131I-Bexxar) for [...]
Lu-177-PSMA-ALB-56
177Lu-PSMA-ALB-56 is a radiolabeled PSMA analogue developed for prostate cancer [...]
Lu-177-PNT6555
177Lu-PNT6555 (part of the PNT2004 development program) is a molecule [...]
Lu-177-Ludotadipep
177Lu-Ludotadipep (177Lu-FC705) is a 177Lu-labeled analogue of 177Lu-Vipivotide targeting PSMA. [...]
Lu-177-rhPSMA-10.1
rhPSMA (radiohybrid PSMA) is a prostate specific membrane antigen labeled [...]
Lu-177-Oxodotreotide (Lutathera®)
177Lu-Oxodotreotide (177Lu-Lutathera®, 177Lu-DOTATATE) is a radiolabeled somatostatin analogue developed [...]
Lu-177-EDTMP
177Lu-EDTMP is the 177Lu equivalent of 153Sm-Lexidronam developed for the same [...]
Lu-177-DOTAZOL
177Lu-DOTAZOL is a drug suitable for betatherapy of bone metastases [...]
Lu-177-Rosopatamab
177Lu-Rosopatamab (177Lu-J591, 177Lu-TLX591, 177Lu-J591, 177Lu-ATL-101) is the Lutetium-177 labeled [...]
Lu-177-ST2210 (IART – Lu-177 DOTA-Biotin)
IART® stands for Intraoperative Avidination for Radionuclide Treatment. It is [...]